Zhengye Biotechnology Holding (ZYBT) Assets Average (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Assets Average of $66.0 million for Q4 2025, down 4.43% year-on-year from $69.0 million in Q4 2024, and down 5.12% on a QoQ basis from $69.6 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Assets Average (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Assets Average for 2 consecutive years, with $66.0 million the latest figure, recorded in Q4 2025.
- Quarterly Assets Average fell 4.43% year-over-year to $66.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $66.0 million (down 4.43% YoY) and the FY2025 annual result came in at $65.0 million, down 5.12% from the prior year.
- Assets Average fell to $66.0 million in Q4 2025 per ZYBT's latest filing, from $69.6 million in the prior quarter.
- Over the last five years, Assets Average for ZYBT reached as high as $69.6 million in Q2 2025 and fell as low as $66.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Zhengye Biotechnology Holding | 85.23 Mn | 85.93 Mn | - | 65.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.99 Mn |
| Jun 30, 2025 | 69.56 Mn |
| Dec 31, 2024 | 69.05 Mn |